Business
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
Semnur’s shares of common stock and warrants are expected to continue to trade on the OTC Markets under the ticker symbols “SMNR” and “SMNRW”, respectively.Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock post Business Combination PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain
About this update from Scilex Holding Company
[{"type":"image","alt":"Scilex Holding Company","displaySize":"","headline":null,"caption":"Scilex Holding Company","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/9b2e3809b02a2a884909cf9194da8b1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BaZBI9MyaHmZ0IuVZrA_gg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9b2e3809b02a2a884909cf9194da8b1d","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Semnur’s shares of common stock and warrants are expected to continue to trade on the OTC Markets under the ticker symbols “SMNR” and “SMNRW”, respectively.","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock post Business Combination","length":111,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":267,"olType":false},{"type":"text","content":"PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its majority-owned subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp (“Denali”), a special purpose acquisition company, announced the closing of their previously announced business combination (the "Business Combination").","length":639,"tagName":"p"},{"type":"text","content":"The combined company will operate as “Semnur Pharmaceuticals, Inc.” and its shares of common stock and warrants are expected to continue trading on the OTC Markets under the ticker symbols “SMNR” and “SMNRW”, respectively.","length":222,"tagName":"p"},{"type":"text","content":"“Semnur is entering an exciting phase as the resources of the public capital markets will be available to enhance our business growth and enable us to continue to fulfill our mission to address patient non-opioid pain management needs”, said Henry Ji, Ph.D., Executive Chairman and Chief Executive Officer and President of Scilex and Executive Chairperson of Semnur. “Our uni...